A Phase I Study Using Most Closely HLA-matched Adenovirus-specific T Lymphocytes for the Treatment of Adenovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-A)
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Adenovirus specific T cells ViraCyte (Primary)
- Indications Adenovirus infections
- Focus Adverse reactions
- Acronyms VIRALYM-A
- Sponsors ViraCyte
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.
- 14 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018.
- 01 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Dec 2017.